A Science and Technology Blog
The first serosurvey was carried out in August-September 2020 and the six-month follow-up was carried out in end-January to February 2021. Widespread asymptomatic infection by mid-September when the daily cases…
The increase in daily cases has been very steep — from over 12,200 cases on March 1 to over 1,26,000 on April 7. The doubling time has reduced from 504…
In all, 492 severe and serious AEFI have been classified by the AEFI Secretariat of the immunisation technical support unit (ITSU) at the Health Ministry. Classification has been completed for…
Names of the ten members Dr. Varsha Gupta, Professor, Department of Microbiology, Government Medical College Hospital, Chandigarh; 2) Dr. Archana Thakur, Medical Director, Professor and HOD (Microbiology), G.B. Pant Hospital,…
The rate of increase in cases in India during March has been faster than at any other time during the pandemic, which is also reflected in the modelling studies by…
The Subject Expert Committee (SEC) has permitted Bharat Biotech to unblind all phase-3 trial participants above 45 years and offer the vaccine to those who received a placebo. The reason: vaccines (including Covaxin) are already available under the immunisation programme, and therefore all the eligible age groups should be unblinded for vaccination.
Developed by Washington University School of Medicine in St. Louis, the vaccine has been licensed to Bharat Biotech to carry out human clinical trials, manufacture the vaccine and distribute them…
By following the U.K. model of vaccinating people based on age bands rather than focussing on comorbidities, millions of people would become eligible to receive the vaccine and be fully…
